Bortezomib (PS341) is a potent, selective, competitive, orally active Proteasome inhibitor with Ki of 0.6 nM for 20S Proteasome.
Bortezomib (PS341) shows only modest activity toward serine and thiol proteases (cathepsin G, elastase, chymotrypsin Ki>300 nM).
Bortezomib (PS341) inhibits the TNFα-stimulated activation of NF-κB in primary HUVE cells (IC50=0.5 uM) by blocking the degradation of the inhibitor IκBα.
Bortezomib (PS341) exhibits anti-inflammatory effects in vivo.
